Anemia drugs raise heart risks in kidney patients, CMS panel says

03/25/2010 | Reuters

A CMS advisory panel concluded that high doses of erythropoiesis-stimulating agents used to treat anemia increased heart risks in patients with chronic kidney disease. The panel was convened to determine whether updated guidelines are necessary on the use of Johnson & Johnson's Procrit and Amgen's Aranesp and Epogen.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC